[{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"LML134","moa":"5-HT6 receptor","graph1":"Sleep","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Icon Plc","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"FINLAND","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Tasipimidine","moa":"Alpha-2A adrenergic receptor","graph1":"Sleep","graph2":"Phase II","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Solution","sponsorNew":"Orion Corporation \/ Icon Plc","highestDevelopmentStatusID":"8","companyTruncated":"Orion Corporation \/ Icon Plc"},{"orgOrder":0,"company":"Defined Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Sleep","graph2":"Phase II","graph3":"Defined Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Defined Research \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Defined Research \/ Undisclosed"},{"orgOrder":0,"company":"St. Joseph's Healthcare Hamilton","sponsor":"McMaster University","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Sleep","graph2":"Phase II","graph3":"St. Joseph's Healthcare Hamilton","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"St. Joseph's Healthcare Hamilton \/ McMaster University","highestDevelopmentStatusID":"8","companyTruncated":"St. Joseph's Healthcare Hamilton \/ McMaster University"},{"orgOrder":0,"company":"MediPharm Labs","sponsor":"McMaster University","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Agreement","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Sleep","graph2":"Phase II","graph3":"MediPharm Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oil","sponsorNew":"MediPharm Labs \/ McMaster University","highestDevelopmentStatusID":"8","companyTruncated":"MediPharm Labs \/ McMaster University"},{"orgOrder":0,"company":"MediPharm Labs","sponsor":"McMaster University","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Sleep","graph2":"Phase II","graph3":"MediPharm Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oil","sponsorNew":"MediPharm Labs \/ McMaster University","highestDevelopmentStatusID":"8","companyTruncated":"MediPharm Labs \/ McMaster University"},{"orgOrder":0,"company":"Bod Australia","sponsor":"Woolcock Institute of Medical Research","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"AUSTRALIA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Sleep","graph2":"Phase II","graph3":"Bod Australia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bod Australia \/ Woolcock Institute of Medical Research","highestDevelopmentStatusID":"8","companyTruncated":"Bod Australia \/ Woolcock Institute of Medical Research"},{"orgOrder":0,"company":"RespireRx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"Cannabinoid CB1 receptor","graph1":"Sleep","graph2":"Phase II","graph3":"RespireRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RespireRx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"RespireRx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"RespireRx Pharmaceuticals","sponsor":"ResolutionRx","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Licensing Agreement","leadProduct":"Tetrahydrocannabinol","moa":"Cannabinoid CB1 receptor","graph1":"Sleep","graph2":"Phase II","graph3":"RespireRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RespireRx Pharmaceuticals \/ ResolutionRx","highestDevelopmentStatusID":"8","companyTruncated":"RespireRx Pharmaceuticals \/ ResolutionRx"},{"orgOrder":0,"company":"RespireRx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"Cannabinoid CB1 receptor","graph1":"Sleep","graph2":"Phase II","graph3":"RespireRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RespireRx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"RespireRx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"RespireRx Pharmaceuticals","sponsor":"University Of Illinois Chicago","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Licensing Agreement","leadProduct":"Tetrahydrocannabinol","moa":"Cannabinoid CB1 receptor","graph1":"Sleep","graph2":"Phase II","graph3":"RespireRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RespireRx Pharmaceuticals \/ University Of Illinois Chicago","highestDevelopmentStatusID":"8","companyTruncated":"RespireRx Pharmaceuticals \/ University Of Illinois Chicago"},{"orgOrder":0,"company":"RespireRx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"Cannabinoid CB1 receptor","graph1":"Sleep","graph2":"Phase II","graph3":"RespireRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RespireRx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"RespireRx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ab Initio Pharma","sponsor":"ResolutionRx","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"AUSTRALIA","productType":"Controlled Substance","year":"2023","type":"Agreement","leadProduct":"Tetrahydrocannabinol","moa":"Cannabinoid CB1 receptor","graph1":"Sleep","graph2":"Phase II","graph3":"Ab Initio Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ab Initio Pharma \/ ResolutionRx","highestDevelopmentStatusID":"8","companyTruncated":"Ab Initio Pharma \/ ResolutionRx"},{"orgOrder":0,"company":"Desitin Arzneimittel","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"GERMANY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sulthiame","moa":"Carbonic anhydrase","graph1":"Sleep","graph2":"Phase II","graph3":"Desitin Arzneimittel","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Desitin Arzneimittel \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Desitin Arzneimittel \/ Undisclosed"},{"orgOrder":0,"company":"Desitin Arzneimittel","sponsor":"Apnimed","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"GERMANY","productType":"Miscellaneous","year":"2025","type":"Acquisition","leadProduct":"Sulthiame","moa":"Carbonic anhydrase","graph1":"Sleep","graph2":"Phase II","graph3":"Desitin Arzneimittel","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Desitin Arzneimittel \/ Apnimed","highestDevelopmentStatusID":"8","companyTruncated":"Desitin Arzneimittel \/ Apnimed"},{"orgOrder":0,"company":"Mineralys Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Lorundrostat","moa":"CYP11B2","graph1":"Sleep","graph2":"Phase II","graph3":"Mineralys Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mineralys Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mineralys Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Balance Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"BTD-001","moa":"GABA A receptor","graph1":"Sleep","graph2":"Phase II","graph3":"Balance Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Balance Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Balance Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Intec Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SLOVAKIA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Zaleplon","moa":"GABA A receptor alpha-1\/beta-1\/gamma-2","graph1":"Sleep","graph2":"Phase II","graph3":"Intec Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intec Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Intec Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Zolpidem Tartrate","moa":"GABA A receptor alpha-1\/beta-1\/gamma-2","graph1":"Sleep","graph2":"Phase II","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Idorsia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Idorsia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Balance Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Pentylenetetrazole","moa":"GABA receptor","graph1":"Sleep","graph2":"Phase II","graph3":"Balance Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Balance Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Balance Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Umecrine Cognition","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWEDEN","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Golexanolone","moa":"GABAA receptor","graph1":"Sleep","graph2":"Phase II","graph3":"Umecrine Cognition","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Umecrine Cognition \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Umecrine Cognition \/ Undisclosed"},{"orgOrder":0,"company":"Stanford University","sponsor":"Avadel Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Sodium Oxybate","moa":"GABA-B receptor","graph1":"Sleep","graph2":"Phase II","graph3":"Stanford University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Stanford University \/ Avadel Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Stanford University \/ Avadel Pharmaceuticals"},{"orgOrder":0,"company":"Brigham and Women's Hospital","sponsor":"Apnimed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"AD036","moa":"GPR119","graph1":"Sleep","graph2":"Phase II","graph3":"Brigham and Women's Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Brigham and Women's Hospital \/ Apnimed","highestDevelopmentStatusID":"8","companyTruncated":"Brigham and Women's Hospital \/ Apnimed"},{"orgOrder":0,"company":"Apnimed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"AD036","moa":"GPR119","graph1":"Sleep","graph2":"Phase II","graph3":"Apnimed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Apnimed \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Apnimed \/ Undisclosed"},{"orgOrder":0,"company":"Apnimed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"AD036","moa":"GPR119","graph1":"Sleep","graph2":"Phase II","graph3":"Apnimed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Apnimed \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Apnimed \/ Undisclosed"},{"orgOrder":0,"company":"Theranexus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"FRANCE","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"THN102","moa":"H3 receptor\/Dopamine transporter","graph1":"Sleep","graph2":"Phase II","graph3":"Theranexus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Theranexus \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Theranexus \/ Undisclosed"},{"orgOrder":0,"company":"Suven Life Sciences Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"INDIA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Samelisant","moa":"Histamine H3 receptor","graph1":"Sleep","graph2":"Phase II","graph3":"Suven Life Sciences Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Suven Life Sciences Limited \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Suven Life Sciences Limited \/ Undisclosed"},{"orgOrder":0,"company":"Suven Life Sciences Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"INDIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Samelisant","moa":"Histamine H3 receptor","graph1":"Sleep","graph2":"Phase II","graph3":"Suven Life Sciences Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Suven Life Sciences Limited \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Suven Life Sciences Limited \/ Undisclosed"},{"orgOrder":0,"company":"Suven Life Sciences Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"INDIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Samelisant","moa":"Histamine H3 receptor","graph1":"Sleep","graph2":"Phase II","graph3":"Suven Life Sciences Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Suven Life Sciences Limited \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Suven Life Sciences Limited \/ Undisclosed"},{"orgOrder":0,"company":"PrecisionBiotics Group Ltd.","sponsor":"Nottingham Trent University | Atlantia Food Clinical Trials Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"IRELAND","productType":"Probiotic","year":"2019","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Sleep","graph2":"Phase II","graph3":"PrecisionBiotics Group Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PrecisionBiotics Group Ltd. \/ Nottingham Trent University | Atlantia Food Clinical Trials Ltd.","highestDevelopmentStatusID":"8","companyTruncated":"PrecisionBiotics Group Ltd. \/ Nottingham Trent University | Atlantia Food Clinical Trials Ltd."},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"Kuhnil Pharmaceutical, Co. Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Sleep","graph2":"Phase II","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seoul National University Hospital \/ Kuhnil Pharmaceutical, Co. Ltd","highestDevelopmentStatusID":"8","companyTruncated":"Seoul National University Hospital \/ Kuhnil Pharmaceutical, Co. Ltd"},{"orgOrder":0,"company":"Neurim Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"ISRAEL","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Neu-P11","moa":"Melatonin receptor","graph1":"Sleep","graph2":"Phase II","graph3":"Neurim Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Neurim Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Neurim Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Neurim Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"ISRAEL","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Neu-P11","moa":"Melatonin receptor","graph1":"Sleep","graph2":"Phase II","graph3":"Neurim Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Neurim Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Neurim Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Mazindol","moa":"Monoamine transporter","graph1":"Sleep","graph2":"Phase II","graph3":"NLS Pharmaceutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NLS Pharmaceutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NLS Pharmaceutics \/ Undisclosed"},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Mazindol","moa":"Monoamine transporter","graph1":"Sleep","graph2":"Phase II","graph3":"NLS Pharmaceutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NLS Pharmaceutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NLS Pharmaceutics \/ Undisclosed"},{"orgOrder":0,"company":"Adare Pharma Solutions","sponsor":"NLS Pharmaceutics","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Collaboration","leadProduct":"Mazindol","moa":"Monoamine transporter","graph1":"Sleep","graph2":"Phase II","graph3":"Adare Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Adare Pharma Solutions \/ NLS Pharmaceutics","highestDevelopmentStatusID":"8","companyTruncated":"Adare Pharma Solutions \/ NLS Pharmaceutics"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"GERMANY","productType":"Plant Extract\/Herbal","year":"2014","type":"Inapplicable","leadProduct":"Ginseng G115 Extract","moa":"Multiple (e.g., AMPK, NO synthase)","graph1":"Sleep","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"GERMANY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Elinzanetant","moa":"Neurokinin 1 receptor | Neurokinin 3 receptor","graph1":"Sleep","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Imbrium Therapeutics","sponsor":"Purdue Pharmaceuticals L.P","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Sunobinop","moa":"NOP receptor||Undisclosed","graph1":"Sleep","graph2":"Phase II","graph3":"Imbrium Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Imbrium Therapeutics \/ Purdue Pharmaceuticals L.P","highestDevelopmentStatusID":"8","companyTruncated":"Imbrium Therapeutics \/ Purdue Pharmaceuticals L.P"},{"orgOrder":0,"company":"Imbrium Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sunobinop","moa":"NOP receptor","graph1":"Sleep","graph2":"Phase II","graph3":"Imbrium Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Imbrium Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Imbrium Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Istituto Auxologico Italiano","sponsor":"YGHEA, CRO Division of Ecol Studio spa | STM Pharma PRO srl | Apnimed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"ITALY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"AD128","moa":"Norepinephrine transporter","graph1":"Sleep","graph2":"Phase II","graph3":"Istituto Auxologico Italiano","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Istituto Auxologico Italiano \/ YGHEA, CRO Division of Ecol Studio spa | STM Pharma PRO srl | Apnimed","highestDevelopmentStatusID":"8","companyTruncated":"Istituto Auxologico Italiano \/ YGHEA, CRO Division of Ecol Studio spa | STM Pharma PRO srl | Apnimed"},{"orgOrder":0,"company":"Zevra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Norepinephrine transporter","graph1":"Sleep","graph2":"Phase II","graph3":"Zevra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Zevra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zevra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Zevra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Norepinephrine transporter","graph1":"Sleep","graph2":"Phase II","graph3":"Zevra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Zevra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zevra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"KemPharm","sponsor":"Hypersomnia Foundation","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Partnership","leadProduct":"Dexmethylphenidate","moa":"Norepinephrine transporter","graph1":"Sleep","graph2":"Phase II","graph3":"KemPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"KemPharm \/ Hypersomnia Foundation","highestDevelopmentStatusID":"8","companyTruncated":"KemPharm \/ Hypersomnia Foundation"},{"orgOrder":0,"company":"KemPharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Norepinephrine transporter","graph1":"Sleep","graph2":"Phase II","graph3":"KemPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"KemPharm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"KemPharm \/ Undisclosed"},{"orgOrder":0,"company":"Zevra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Norepinephrine transporter","graph1":"Sleep","graph2":"Phase II","graph3":"Zevra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Zevra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zevra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Zevra Therapeutics","sponsor":"RARE-X","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Collaboration","leadProduct":"Dexmethylphenidate","moa":"Norepinephrine transporter","graph1":"Sleep","graph2":"Phase II","graph3":"Zevra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Zevra Therapeutics \/ RARE-X","highestDevelopmentStatusID":"8","companyTruncated":"Zevra Therapeutics \/ RARE-X"},{"orgOrder":0,"company":"KemPharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Norepinephrine transporter","graph1":"Sleep","graph2":"Phase II","graph3":"KemPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"KemPharm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"KemPharm \/ Undisclosed"},{"orgOrder":0,"company":"KemPharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Norepinephrine transporter","graph1":"Sleep","graph2":"Phase II","graph3":"KemPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"KemPharm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"KemPharm \/ Undisclosed"},{"orgOrder":0,"company":"KemPharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Norepinephrine transporter","graph1":"Sleep","graph2":"Phase II","graph3":"KemPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"KemPharm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"KemPharm \/ Undisclosed"},{"orgOrder":0,"company":"KemPharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Norepinephrine transporter","graph1":"Sleep","graph2":"Phase II","graph3":"KemPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"KemPharm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"KemPharm \/ Undisclosed"},{"orgOrder":0,"company":"KemPharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Norepinephrine transporter","graph1":"Sleep","graph2":"Phase II","graph3":"KemPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"KemPharm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"KemPharm \/ Undisclosed"},{"orgOrder":0,"company":"Apnimed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Viloxazine Hydrochloride","moa":"Norepinephrine transporter","graph1":"Sleep","graph2":"Phase II","graph3":"Apnimed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Apnimed \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Apnimed \/ Undisclosed"},{"orgOrder":0,"company":"Zevra Therapeutics","sponsor":"Rho Inc","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Serdexmethylphenidate","moa":"Norepinephrine transporter | Dopamine transporter","graph1":"Sleep","graph2":"Phase II","graph3":"Zevra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zevra Therapeutics \/ Rho Inc","highestDevelopmentStatusID":"8","companyTruncated":"Zevra Therapeutics \/ Rho Inc"},{"orgOrder":0,"company":"University of Maryland, Baltimore","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Suvorexant","moa":"Orexin receptor","graph1":"Sleep","graph2":"Phase II","graph3":"University of Maryland, Baltimore","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Maryland, Baltimore \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"University of Maryland, Baltimore \/ Merck & Co"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Good Ventures | Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Suvorexant","moa":"Orexin receptor","graph1":"Sleep","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Good Ventures | Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Good Ventures | Merck & Co"},{"orgOrder":0,"company":"The Florey Institute of Neuroscience and Mental Health","sponsor":"St Vincent's Hospital Melbourne | Melbourne Health","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"AUSTRALIA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Suvorexant","moa":"Orexin receptor","graph1":"Sleep","graph2":"Phase II","graph3":"The Florey Institute of Neuroscience and Mental Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Florey Institute of Neuroscience and Mental Health \/ St Vincent's Hospital Melbourne | Melbourne Health","highestDevelopmentStatusID":"8","companyTruncated":"The Florey Institute of Neuroscience and Mental Health \/ St Vincent's Hospital Melbourne | Melbourne Health"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"TAK-994","moa":"Orexin receptor","graph1":"Sleep","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"TAK-994","moa":"Orexin receptor","graph1":"Sleep","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"TAK-994","moa":"Orexin receptor","graph1":"Sleep","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"TAK-994","moa":"Orexin receptor","graph1":"Sleep","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Eisai Inc","sponsor":"Purdue Pharmaceuticals L.P","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2016","type":"Inapplicable","leadProduct":"Lemborexant","moa":"Orexin receptor 1 | Orexin receptor 2","graph1":"Sleep","graph2":"Phase II","graph3":"Eisai Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisai Inc \/ Purdue Pharmaceuticals L.P","highestDevelopmentStatusID":"8","companyTruncated":"Eisai Inc \/ Purdue Pharmaceuticals L.P"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2015","type":"Inapplicable","leadProduct":"Seltorexant","moa":"Orexin receptor 2","graph1":"Sleep","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2017","type":"Inapplicable","leadProduct":"Seltorexant","moa":"Orexin receptor 2","graph1":"Sleep","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Agreement","leadProduct":"Seltorexant","moa":"Orexin receptor 2","graph1":"Sleep","graph2":"Phase II","graph3":"Minerva Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Minerva Neurosciences \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Minerva Neurosciences \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"IRELAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ALKS 2680","moa":"OX2 receptor","graph1":"Sleep","graph2":"Phase II","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alkermes Plc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alkermes Plc \/ Undisclosed"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"IRELAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ALKS 2680","moa":"OX2 receptor","graph1":"Sleep","graph2":"Phase II","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alkermes Plc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alkermes Plc \/ Undisclosed"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"IRELAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ALKS 2680","moa":"OX2 receptor","graph1":"Sleep","graph2":"Phase II","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alkermes Plc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alkermes Plc \/ Undisclosed"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"IRELAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ALKS 2680","moa":"OX2 receptor","graph1":"Sleep","graph2":"Phase II","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alkermes Plc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alkermes Plc \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Danavorexton","moa":"OX2R","graph1":"Sleep","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Danavorexton","moa":"OX2R","graph1":"Sleep","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Apnimed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Sivopixant","moa":"||P2RX3","graph1":"Sleep","graph2":"Phase II","graph3":"Apnimed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Apnimed \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Apnimed \/ Undisclosed"},{"orgOrder":0,"company":"Shionogi Apnimed Sleep Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Sivopixant","moa":"P2RX3","graph1":"Sleep","graph2":"Phase II","graph3":"Shionogi Apnimed Sleep Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shionogi Apnimed Sleep Science \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shionogi Apnimed Sleep Science \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"GERMANY","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"BAY2253651","moa":"Potassium channel","graph1":"Sleep","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Axsome Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"Reboxetine Mesylate","moa":"SLC6A2","graph1":"Sleep","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0.33000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0.33000000000000002,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Axsome Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Axsome Therapeutics"},{"orgOrder":0,"company":"G\u00f6teborg University","sponsor":"Eisai Inc","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWEDEN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Zonisamide","moa":"Sodium channel alpha subunit","graph1":"Sleep","graph2":"Phase II","graph3":"G\u00f6teborg University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"G\u00f6teborg University \/ Eisai Inc","highestDevelopmentStatusID":"8","companyTruncated":"G\u00f6teborg University \/ Eisai Inc"},{"orgOrder":0,"company":"Syntara Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"AUSTRALIA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"BI 1467335","moa":"Sphingosine kinase 2","graph1":"Sleep","graph2":"Phase II","graph3":"Syntara Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syntara Limited \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Syntara Limited \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"IRELAND","productType":"Controlled Substance","year":"2010","type":"Inapplicable","leadProduct":"Lisdexamfetamine Dimesylate","moa":"Synaptic vesicular amine transporter | Dopamine transporter | Norepinephrine transporter","graph1":"Sleep","graph2":"Phase II","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"BAY2586116","moa":"TASK1\/TASK3","graph1":"Sleep","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Solution","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"GERMANY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"BAY2586116","moa":"TASK1\/TASK3","graph1":"Sleep","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Spray","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"GERMANY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"BAY2586116","moa":"TASK1\/TASK3","graph1":"Sleep","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Apnimed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"AD113","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase II","graph3":"Apnimed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Apnimed \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Apnimed \/ Undisclosed"},{"orgOrder":0,"company":"Apnimed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"AD182","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase II","graph3":"Apnimed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Apnimed \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Apnimed \/ Undisclosed"},{"orgOrder":0,"company":"Heel","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"GERMANY","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Avena Sativa","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase II","graph3":"Heel","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Heel \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Heel \/ Undisclosed"},{"orgOrder":0,"company":"BenevolentAI","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"BEN-2001","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase II","graph3":"BenevolentAI","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BenevolentAI \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BenevolentAI \/ Undisclosed"},{"orgOrder":0,"company":"Canopy Growth Corporation","sponsor":"Galenova Inc | Algorithme Pharma Inc. | H\u00f4pital du Sacre-C\u0153ur de Montr\u00e9al | McGill University Health Centre Research Institute | Centre Hospitalier de l'Universite de Montreal","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"CANADA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"CHI-921","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase II","graph3":"Canopy Growth Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Canopy Growth Corporation \/ Galenova Inc | Algorithme Pharma Inc. | H\u00f4pital du Sacre-C\u0153ur de Montr\u00e9al | McGill University Health Centre Research Institute | Centre Hospitalier de l'Universite de Montreal","highestDevelopmentStatusID":"8","companyTruncated":"Canopy Growth Corporation \/ Galenova Inc | Algorithme Pharma Inc. | H\u00f4pital du Sacre-C\u0153ur de Montr\u00e9al | McGill University Health Centre Research Institute | Centre Hospitalier de l'Universite de Montreal"},{"orgOrder":0,"company":"Northwell Health","sponsor":"Staten Island University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Heliox","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase II","graph3":"Northwell Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northwell Health \/ Staten Island University Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Northwell Health \/ Staten Island University Hospital"},{"orgOrder":0,"company":"EMS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"BRAZIL","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Hipnos 3","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase II","graph3":"EMS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"EMS \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EMS \/ Undisclosed"},{"orgOrder":0,"company":"Intec Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SLOVAKIA","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"IN 10 003","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase II","graph3":"Intec Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intec Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Intec Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ORX750","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase II","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sosei Group Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sosei Group Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Centessa Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"ORX750","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase II","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sosei Group Corporation \/ Centessa Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Sosei Group Corporation \/ Centessa Pharmaceuticals"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ORX750","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase II","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Centessa Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Centessa Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Sosei Group Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ORX750","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase II","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Centessa Pharmaceuticals \/ Sosei Group Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Centessa Pharmaceuticals \/ Sosei Group Corporation"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ORX750","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase II","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Centessa Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Centessa Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ORX750","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase II","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Centessa Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Centessa Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"ORX750","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase II","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centessa Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Centessa Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"IRELAND","productType":"Controlled Substance","year":"2017","type":"Inapplicable","leadProduct":"Solriamfetol Hydrochloride","moa":"Dopamine\/norepinephrine transporter||Undisclosed","graph1":"Sleep","graph2":"Phase II","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jazz Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Jazz Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"TAK-360","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"TAK-360","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"SciSparc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"ISRAEL","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"THX-110","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SciSparc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SciSparc \/ Undisclosed"},{"orgOrder":0,"company":"Taisho Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"TS-091","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase II","graph3":"Taisho Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taisho Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Taisho Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"LALLEMAND HEALTH SOLUTIONS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"CANADA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase II","graph3":"LALLEMAND HEALTH SOLUTIONS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LALLEMAND HEALTH SOLUTIONS \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"LALLEMAND HEALTH SOLUTIONS \/ Undisclosed"}]
Find Drugs for Sleep in Phase II Clinical Development
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
